Setup

Medpace is a full-service CRO for small and mid-cap biopharma, with premium operating margins (21% EBITDA) among listed peers. The Q1 2026 10-Q is the second consecutive quarter where management's publicly stated book-to-bill target (1.15+, set on the April 22, 2025 call) missed by a wide margin (0.88x). The miss is the subject of an active securities fraud class action, and the peer CROs that have reported all showed recovering book-to-bill — making MEDP the outlier, not the canary.

What the filing says

Q1 2026 revenue $706.6M (+26.5% YoY), but most of the growth was pass-through — reimbursable OOP expenses +54.1% to $312M; net service costs +11.5%. EBITDA $149.4M, margin 21.1% (flat YoY). Net income margin fell 300bps to 17.5% — entirely tax normalization (ETR 16.1% vs 3.0%).

The critical figure: net new business awards $618.4M ÷ revenue $706.6M = book-to-bill 0.88x. Ending backlog $2,929M, declining sequentially from the ≈$3,000M Q3/Q4 2025 peak. Trajectory: Q1 2025 0.90x → Q4 2025 1.04x → Q1 2026 0.88x. On the April 23 call, CEO Troendle attributed cancellations to "typical project-specific issues like product performance and re-prioritizations, not macroeconomic factors," and confirmed RFPs were down both sequentially AND year-over-year — a statement no other CRO has made this cycle.

Three same-day developments:

1. Active securities fraud class action (Durbin v. Medpace, S.D. Ohio, filed April 6) names CEO, CFO, and President Geiger for the 1.15 guidance. Lead plaintiff deadline June 8.
2. President Jesse Geiger retires May 31; CEO Troendle reassumes the role. Geiger is named in the suit.
3. Zero share repurchases in Q1 2026 against $821M authorization remaining, vs $389.8M deployed Q1 2025.

Cash $652.7M, zero debt. FCF ≈$145M. Metabolic (primarily GLP-1 trials) is 33.6% of revenue and grew +60.5% YoY — concentration risk if metabolic cancellations rise or biotech funding for GLP-1 programs contracts.

What the market thinks

Stock ≈$410, down 35% from peak. Forward P/E ≈24x on midpoint guide EPS $17.09. Mean analyst target $489 (+19% upside), no meaningful post-Q1 downgrades. Options: near-term IV crushed, Dec IV 52%, Sep IV 80%, flat put skew, OI put/call 0.20. Short interest 5.3%.

State probabilities decoded from term-structure bifurcation and flat skew (low near-term move priced, Q2 binary priced modestly): Recovery ≈30%, Stall ≈40%, Idio-confirms ≈25%, Tail ≈5%, yielding implied E[return] ≈ -15%. Our probabilities — based on peer divergence, CEO's own attribution, and backlog trajectory — are 20 / 35 / 35 / 10, yielding E[return] ≈ -21%. Gap: ≈6pp pre-peer-validation; narrower after the May prints.

Where the stock "should" trade

Triangulation on the four states, using EPS sensitivity + multiple re-rating:

Pattern comps: FTRE post-BTB break re-rated to 14x; ICLR audit overhang stuck at 15x. The 24x multiple requires the quality-margin premium, which the broken BTB and distracted dual-role CEO erode.

Why the gap exists

Peer CRO divergence is not synthesized in consensus. IQV Q4 2025 1.18x (record $32.7B backlog, RFPs +double-digit), CRL DSA Q4 2025 1.12x (recovering from 0.80x trough), FTRE Q4 2025 1.14x ("historic low cancellations"). ICLR is weak but confounded by an audit-committee revenue investigation (separate issue). IQV carries its own AI-disruption narrative that has compressed its multiple, but none of these peers is reporting a BTB deterioration on the MEDP pattern. Biotech funding backdrop is supportive: XBI +65% 1Y; Q1 2026 biopharma IPOs $1.7B, highest since 2021.

The post-Feb 10 market narrative was "transitory cancellation spike, sector-wide weakness." Peer prints disprove this; management's own attribution rules out macro. Sell-side targets still imply +19% upside on a 24x multiple that peer CROs don't earn.

Buyback hoarding is a separate signal. An aggressive historical repurchaser deploying zero against $821M authorization while the stock falls is itself information — consistent with lawsuit-defense posture, pending M&A, or undisclosed deterioration.

Risks (ranked by impact)

1. Buyback redeployment. A $200M+ ASR announcement would substantially change the thesis. P(announced before Q2) ≈30%.
2. Sector drag. β to peer basket likely 0.7-0.9; a pair structure (MEDP vs CRL + FTRE; omit IQV because of its own AI idio narrative) is cleaner than a naked expression for isolating the divergence.
3. Stall scenario. ≈25% probability of Q2 BTB printing 1.00-1.10 — relief rally without a guide cut.
4. Forensic signal unverified. Research surfaced a claim of a Geiger $14.4M sale on Mar 17 that could not be verified in the Form 4 filings checked (Mar 19 filing is Burwig, not Geiger). Not included in the thesis magnitude.
5. Early lawsuit dismissal. Low probability but removes an overhang.

How the thesis expresses

Idiosyncratic variance is estimated 25-40% (below the 75% clean-idio threshold), which is why factor hedging matters — iev regress MEDP is the prerequisite before sizing. A pair expression — long recovering CRO peers (CRL + FTRE equal-weight; omit IQV for its own AI overhang) against MEDP — isolates the BTB divergence from sector noise. Optionality on the idio-confirms scenario sits in Dec 2026 $400/$350 put spreads, entered after peer Q1 prints validate the divergence read (May 20 window). The $821M unused authorization is the primary tail risk on any expression with naked downside.

Catalysts

The gap likely closes between May 20 (peer validation) and Q2 earnings. Narrow execution window.

What would change our mind

• MEDP announces $200M+ buyback or ASR before Q2 — thesis broken.
• 2 or more of IQV / CRL / FTRE print Q1 2026 BTB below 1.0 — partial sectoral read; MEDP shifts from outlier to canary.
• Q2 2026 BTB prints >1.10 — cancellation spike was transitory; revert to bull base.
• External growth-CRO executive replaces Geiger — operational reset signal, not managed exit.
• Geiger Form 4 pull confirms no material open-market sales — forensic pattern absent (doesn't change base case, just removes a contingent edge).

Evidence

Bull evidence (revenue growth, margin stability, balance sheet) is real but lagging. Bear evidence (BTB, lawsuit, departure, hoarding, peer divergence) is forward-looking. Stacked direction bearish; magnitude tempered by the buyback-defense tail.

Memo LR: 0.65 (market hasn't priced the peer-divergence idio reading; expected -15 to -25% over 120d on a well-structured pair).